Meeting Banner
Abstract #4925

Glycine is an early 'biomarker' of blood brain barrier breakdown in Gliomas

Vivek Tiwari1, Zhongxu An1, Yiming Wang1, Michael Levy2, Marco Pinho1,3, Elizabeth A. Maher4,5,6, Edward Pan2,4,5, Toral Patel2,4, Bruce E. Mickey2,5,7, and Changho Choi1,3,5

1Advanced Imaging Research Center, UT Southwestern Medical Center, Dallas, TX, United States, 2Department of Neurological Surgery, UT Southwestern Medical Center, Dallas, TX, United States, 3Department of Radiology, UT Southwestern Medical Center, Dallas, TX, United States, 4Department of Neurology and Neurotherapeutics, UT Southwestern Medical Center, Dallas, TX, United States, 5Harold C. Simmons Cancer Center, UT Southwestern Medical Center, Dallas, TX, United States, 6Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, United States, 7Annette Strauss Center for Neuro-Oncology, UT Southwestern Medical Center, Dallas, TX, United States

Cancer cells may use altered metabolic pathways with respect to their normal counterparts; this metabolic switch is necessary to support their rapid proliferation in oxygen- and nutrient-poor conditions. A few of the metabolites are up-regulated while some others are down-regulated or unaltered. High grade malignant tumors present with enhancement on T1-weighted (T1w) image. Enhancement on post-contrast T1w images is an indicative of breakdown of blood brain barrier (BBB). The increased number of tumor cells may stress the vessels and, thus BBB tend to rupture. A non-invasive bio-marker that can predict the disruption of BBB will be of great clinical significance for assessing the tumor aggressiveness. Here, we show elevated Gly can be a potential bio-marker for predicting the tumor’s potential to present with ruptured BBB.

This abstract and the presentation materials are available to members only; a login is required.

Join Here